Skip to main content

Vasculitis

Behçet's disease

Antibodies

12-04-2022 | Vasculitis | News

ALEVIATE trial: Alemtuzumab may warrant further investigation for refractory vasculitis

Findings from a phase 2b trial suggest that treatment with the anti-CD52 antibody alemtuzumab may be beneficial for some patients with primary systemic vasculitis and an inadequate response to conventional therapies.

17-02-2022 | Cardiovascular disease | News

Premature coronary artery disease risk increased with IMIDs

Individuals with certain immune-mediated inflammatory diseases are at increased risk for premature coronary artery disease, show population-based study data from Taiwan.

Rituximab and rheumatology practice in the COVID-19 era

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

07-11-2021 | ACR 2021 | Conference coverage | News

High rates of severe COVID-19 in patients with vasculitis, polymyalgia rheumatica

An analysis of data from the COVID-19 Global Rheumatology Alliance and EULAR COVID-19 registries suggests high rates of severe COVID-19 among people with primary systemic vasculitis or polymyalgia rheumatica.

Anifrolumab for the treatment of lupus

Anifrolumab for the treatment of SLE

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

New additions to the Adis Journal Club

Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

ACR Convergence 2021 highlights

ACR Convergence 2021

3–9 November: Keep up with the latest news and interviews from the conference.

Febuxostat and cardiovascular risk in people with gout

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

Telemedicine in rheumatology

Telemedicine in rheumatology: COVID-19 and beyond

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

Get ready for ACR Convergence 2020

ACR Convergence 2020

5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

04-03-2020 | Behçet’s disease | News

Apremilast set for EU approval for Behçet’s disease

Click through for more information on this expanded indication

27-02-2020 | Behçet’s disease | News

Behçet’s disease more common than previously thought

The prevalence of Behçet’s disease in the UK is higher than previously estimated, and patients with the disease have an elevated risk for developing cardiovascular and cerebrovascular conditions, researchers report.

13-11-2019 | Behçet’s disease | ACR/ARP 2019 | News

Apremilast reduces oral ulcer burden in Behçet’s syndrome

The small molecule phosphodiesterase 4 inhibitor apremilast reduces the number of oral ulcers and improves quality of life to a greater degree than placebo in people with Behçet’s syndrome, results of the phase III RELIEF study show.

05-08-2019 | Behçet’s disease | News

Real-world data support apremilast for Behçet’s disease

Findings from an Italian real-world study provide support for the phosphodiesterase-4 inhibitor apremilast as a treatment option for people with Behçet’s disease.

05-07-2019 | Behçet’s disease | News

Favorable results with TNF inhibitors in Behçet's disease-associated uveitis

The tumor necrosis factor inhibitors adalimumab and infliximab both show good efficacy when used as first biologic agents in patients with refractory uveitis due to Behçet's disease, Spanish research shows.

02-07-2019 | Behçet’s disease | News

Support for TNF inhibitor use in patients with entero-Behçet’s disease

People with entero-Behçet’s disease and active ulcerative lesions who are treated with tumor necrosis factor inhibitors, either alone or in combination with corticosteroids, are more likely to experience ulcer cure or improvement than those taking corticosteroids alone, researchers report.

17-09-2018 | Large-vessel vasculitis | Review | Article

Diagnosis and differential diagnosis of large-vessel vasculitides

Keser G, Aksu K. Rheumatol Int 2018. doi: 10.1007/s00296-018-4157-3

13-08-2018 | Behçet’s disease | Review | Article

Management of major organ involvement of Behçet’s syndrome: A systematic review for update of the EULAR recommendations

Ozguler Y et al. Rheumatology (Oxford) 2018: key242. doi: 10.1093/rheumatology/key242